
    
      Single centre, open-label, multiple doses, two parallel study groups each receiving two
      formulations in a one-sequence design:

      Group A: Pre-treatment with ESL, treatment with ESL and ascending doses of phenytoin (PHT) in
      last phases;

      Group B: Pre-treatment with PHT, treatment with PHT and ascending doses of ESL in last phases
    
  